SearcharxivSearch

arXiv subjects

David Svensson

Publications and source records attributed to David Svensson.

3 recordsLinked to original sources

Robust Bayesian Sequential Borrowing for Multi-Population Clinical Programmes

We introduce Robust Bayesian Sequential Borrowing (RBSB), a framework for extrapolating evidence across adjacent subgroups in multi-population clinical programmes where studies are conducted in sequence and populations are ordered by clinical proximity. Conventional approaches weight all historical sources uniformly or exclude distant populations entirely, failing to reflect the natural gradient of similarity in such programmes. RBSB encodes the programme order through path-dependent borrowing via robust mixture priors that combine an informative component with a unit-information component to guard against prior-data conflict. Posterior weights, derived in closed form from marginal likelihood ratios, provide transparent dynamic attenuation when heterogeneity arises between sequential populations. The framework supports prospective evaluation of Bayesian Type I error, power, and extends naturally to assurance at both the study and programme level. Simulation studies demonstrate superior false-positive control relative to full pooling, while preserving substantial efficiency gains over standalone analyses. A case study of the START trial illustrates the approach across adult, adolescent, and paediatric populations. RBSB offers a practical, regulator-aligned method for disciplined evidence borrowing that exploits temporal and biological proximity while preventing implausible extrapolation across distant populations.

stat.ME

Overview and practical recommendations on using Shapley Values for identifying predictive biomarkers via CATE modeling

In recent years, two parallel research trends have emerged in machine learning, yet their intersections remain largely unexplored. On one hand, there has been a significant increase in literature focused on Individual Treatment Effect (ITE) modeling, particularly targeting the Conditional Average Treatment Effect (CATE) using meta-learner techniques. These approaches often aim to identify causal effects from observational data. On the other hand, the field of Explainable Machine Learning (XML) has gained traction, with various approaches developed to explain complex models and make their predictions more interpretable. A prominent technique in this area is Shapley Additive Explanations (SHAP), which has become mainstream in data science for analyzing supervised learning models. However, there has been limited exploration of SHAP application in identifying predictive biomarkers through CATE models, a crucial aspect in pharmaceutical precision medicine. We address inherent challenges associated with the SHAP concept in multi-stage CATE strategies and introduce a surrogate estimation approach that is agnostic to the choice of CATE strategy, effectively reducing computational burdens in high-dimensional data. Using this approach, we conduct simulation benchmarking to evaluate the ability to accurately identify biomarkers using SHAP values derived from various CATE meta-learners and Causal Forest.

stat.ME

Modern approaches for evaluating treatment effect heterogeneity from clinical trials and observational data

In this paper we review recent advances in statistical methods for the evaluation of the heterogeneity of treatment effects (HTE), including subgroup identification and estimation of individualized treatment regimens, from randomized clinical trials and observational studies. We identify several types of approaches using the features introduced in Lipkovich, Dmitrienko and D'Agostino (2017) that distinguish the recommended principled methods from basic methods for HTE evaluation that typically rely on rules of thumb and general guidelines (the methods are often referred to as common practices). We discuss the advantages and disadvantages of various principled methods as well as common measures for evaluating their performance. We use simulated data and a case study based on a historical clinical trial to illustrate several new approaches to HTE evaluation.

stat.ME